Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2014 - 2026)

Aclaris Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $102000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 20.31% year-over-year to $102000.0 in Q1 2026; TTM through Mar 2026 was $428000.0, a 38.15% decrease from a year earlier, with the FY2025 full-year figure at $454000.0, down 43.74% from the prior year.
• Depreciation & Amortization (CF) steadied at $102000.0 in Q1 2026 per ACRS's latest filing, from $102000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $243000.0 in Q1 2024 and bottomed at $102000.0 in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $193000.0 (2022), against an average of $177823.5.
• Across the five-year window, Depreciation & Amortization (CF) grew 22.73% in 2024 and slumped 52.89% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $190000.0 in 2022, then gained by 20.0% to $228000.0 in 2023, then plunged by 37.28% to $143000.0 in 2024, then declined by 28.67% to $102000.0 in 2025, then changed by 0.0% to $102000.0 in 2026.
• Per Business Quant, the three latest ACRS Depreciation & Amortization (CF) figures stand at $102000.0 (Q1 2026), $102000.0 (Q4 2025), and $110000.0 (Q3 2025).